Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

889 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of a Prediction Model for Short-Term Remission of Patients with Crohn's Disease Treated with Anti-TNF Drugs.
Medina-Medina R, Iglesias-Flores E, Benítez JM, Marín-Pedrosa S, Salgueiro-Rodríguez I, Linares CI, González-Rubio S, Soto-Escribano P, Gros B, Rodríguez-Perálvarez ML, Cabriada JL, Chaparro M, Gisbert JP, Chicano-Gálvez E, Ortea I, Ferrín G, García-Sánchez V, Aguilar-Melero P. Medina-Medina R, et al. Among authors: gisbert jp. Int J Mol Sci. 2023 May 12;24(10):8695. doi: 10.3390/ijms24108695. Int J Mol Sci. 2023. PMID: 37240037 Free PMC article.
Predictors of response to infliximab in patients with fistulizing Crohn's disease.
Luna-Chadid M, Pérez Calle JL, Mendoza JL, Vera MI, Bermejo AF, Sánchez F, López San Román A, Froilán C, González-Lara V, García-Paredes J, Fernández-Blanco I, Abreu L, Casis B, Solís Herruzo JA, Gisbert JP, Maté Jiménez J. Luna-Chadid M, et al. Among authors: gisbert jp. Rev Esp Enferm Dig. 2004 Jun;96(6):379-81; 382-4. doi: 10.4321/s1130-01082004000600003. Rev Esp Enferm Dig. 2004. PMID: 15230667 Free article. English, Spanish.
Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response.
González-Lama Y, López-San Román A, Marín-Jiménez I, Casis B, Vera I, Bermejo F, Pérez-Calle JL, Taxonera C, Martínez-Silva F, Menchén L, Martínez-Montiel P, Calvo M, Carneros JA, López P, Mendoza JL, Milicua JM, Huerta A, Sánchez F, Abreu L, López-Palacios N, Maté J, Gisbert JP; Group for the Study of Inflammatory Bowel Diseases from Madrid (ENICMAD). González-Lama Y, et al. Among authors: gisbert jp. Gastroenterol Hepatol. 2008 Aug-Sep;31(7):421-6. doi: 10.1157/13125587. Gastroenterol Hepatol. 2008. PMID: 18783686
Can systemic cytokines predict relapse of inflammatory bowel disease?
García-Sánchez V, González R, Iglesias-Flores E, Gisbert JP, Angel-Rey JM, Soto-Escribano P, Gálvez-Calderón C, Reyes-López A, Pérez-Jiménez F, de Dios-Vega JF, Muntané J, Gómez-Camacho F. García-Sánchez V, et al. Among authors: gisbert jp. Hepatogastroenterology. 2010 May-Jun;57(99-100):524-30. Hepatogastroenterology. 2010. PMID: 20698221
Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
García-Sánchez V, Iglesias-Flores E, González R, Gisbert JP, Gallardo-Valverde JM, González-Galilea A, Naranjo-Rodríguez A, de Dios-Vega JF, Muntané J, Gómez-Camacho F. García-Sánchez V, et al. Among authors: gisbert jp. J Crohns Colitis. 2010 Jun;4(2):144-52. doi: 10.1016/j.crohns.2009.09.008. Epub 2009 Dec 2. J Crohns Colitis. 2010. PMID: 21122498
889 results